Allarity Therapeutics, Inc. Common Stock (ALLR) is a publicly traded Healthcare sector company. As of May 21, 2026, ALLR trades at $1.47 with a market cap of $22.11M and a P/E ratio of -2.04. ALLR moved -2.35% today. Year to date, ALLR is +33.04%; over the trailing twelve months it is +35.45%. Its 52-week range spans $0.61 to $2.35. Analyst consensus is buy with an average price target of $9.75. Rallies surfaces ALLR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Allarity Ends Q1 with $29.8M Cash, Secures DRP® Diagnostic Patent, Opens Lung Cancer Trial: Allarity ended Q1 2026 with $29.8 million cash and reduced net loss per share to $0.17 from $0.25. Clinical progress includes FDA Fast Track for advanced ovarian cancer, launch of VA-funded Phase 2 lung cancer trial, and US Notice of Allowance for DRP® companion diagnostic patent.
| Metric | Value |
|---|---|
| Price | $1.47 |
| Market Cap | $22.11M |
| P/E Ratio | -2.04 |
| EPS | $-0.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.35 |
| 52-Week Low | $0.61 |
| Volume | 2.71K |
| Avg Volume | 0 |
| Revenue (TTM) | $345.00K |
| Net Income | $-11.25M |
| Gross Margin | 0.00% |
1 analysts cover ALLR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.75.